about
Cyclooxygenase-3 (COX-3): filling in the gaps toward a COX continuum?Trapping of palindromic ligands within native transthyretin prevents amyloid formationEffects of non-steroidal anti-inflammatory drugs on cyclo-oxygenase and lipoxygenase activity in whole blood from aspirin-sensitive asthmatics vs healthy donors.Origins of prostaglandin E2: involvements of cyclooxygenase (COX)-1 and COX-2 in human and rat systemsInfluence of plasma protein on the potencies of inhibitors of cyclooxygenase-1 and -2Nongenomic signaling of the retinoid X receptor through binding and inhibiting Gq in human plateletsCryptogenic multifocal ulcerating stenosing enteritis associated with homozygous deletion mutations in cytosolic phospholipase A2-αProtocol for a human in vivo model of acute cigarette smoke inhalation challenge in smokers with COPD: monitoring the nasal and systemic immune response using a network biology approachCOX-2 protects against atherosclerosis independently of local vascular prostacyclin: identification of COX-2 associated pathways implicate Rgl1 and lymphocyte networks.Thrombosis is reduced by inhibition of COX-1, but unaffected by inhibition of COX-2, in an acute model of platelet activation in the mouseRole of Toll-like receptors 2 and 4 in the induction of cyclooxygenase-2 in vascular smooth muscle.Nucleotide oligomerization domain 1 is a dominant pathway for NOS2 induction in vascular smooth muscle cells: comparison with Toll-like receptor 4 responses in macrophages.Endogenous epoxygenases are modulators of monocyte/macrophage activityLC-MS/MS confirms that COX-1 drives vascular prostacyclin whilst gene expression pattern reveals non-vascular sites of COX-2 expressionEffects of low-dose aspirin on acute inflammatory responses in humans.Heparin but not citrate anticoagulation of blood preserves platelet function for prolonged periods.Anti-platelet therapy: cyclo-oxygenase inhibition and the use of aspirin with particular regard to dual anti-platelet therapyCyclooxygenases: new forms, new inhibitors, and lessons from the clinic.Pregnane X receptor regulates drug metabolism and transport in the vasculature and protects from oxidative stress.Novel whole blood assay for phenotyping platelet reactivity in mice identifies ICAM-1 as a mediator of platelet-monocyte interactionCyclooxygenase-1, not cyclooxygenase-2, is responsible for physiological production of prostacyclin in the cardiovascular system.COX isoforms in the cardiovascular system: understanding the activities of non-steroidal anti-inflammatory drugs.Evidence that links loss of cyclooxygenase-2 with increased asymmetric dimethylarginine: novel explanation of cardiovascular side effects associated with anti-inflammatory drugsInterleukin-1beta, but not interleukin-6, enhances renal and systemic endothelin production in vivo.Expression and activation of the farnesoid X receptor in the vasculature.Differential COX-2 induction by viral and bacterial PAMPs: Consequences for cytokine and interferon responses and implications for anti-viral COX-2 directed therapies.Blockade of the purinergic P2Y12 receptor greatly increases the platelet inhibitory actions of nitric oxide.Hydrogen sulphide pathway contributes to the enhanced human platelet aggregation in hyperhomocysteinemia.Characterization of multiple platelet activation pathways in patients with bleeding as a high-throughput screening option: use of 96-well Optimul assayAspirin-triggered 15-epi-lipoxin A4 predicts cyclooxygenase-2 in the lungs of LPS-treated mice but not in the circulation: implications for a clinical test.Gasotransmitters and platelets.Farnesoid x receptor ligands inhibit vascular smooth muscle cell inflammation and migration.The farnesoid X receptor is expressed in breast cancer and regulates apoptosis and aromatase expression.The flavonoid quercetin induces apoptosis and inhibits JNK activation in intimal vascular smooth muscle cells.Activation of peroxisome proliferator-activated receptor-gamma by troglitazone (TGZ) inhibits human lung cell growth.Cellular mechanisms of acetaminophen: role of cyclo-oxygenase.Intimal smooth muscle cells as a target for peroxisome proliferator-activated receptor-gamma ligand therapy.COX-1, and not COX-2 activity, regulates airway function: relevance to aspirin-sensitive asthma.Reply to Ricciotti et al.: Evidence for vascular COX isoforms.Antiplatelet effects of aspirin vary with level of P2Y₁₂ receptor blockade supplied by either ticagrelor or prasugrel.
P50
Q24536027-79CF5031-2E99-4076-A6BA-620F98BBBB4BQ27665687-8508A56B-7307-45CF-A84B-2517E7C2820CQ28194198-BABC49B8-8CBE-4EE9-B9EB-7698EEF909FBQ28194243-C0AF45DA-99A0-4E08-A39E-EC785B49E3EBQ28194441-9D3ECBFF-9717-4B5E-B251-A890AED2FFFFQ28217479-DE848099-7BE5-4402-BEBD-DEC398087CB2Q28282217-6C136197-11D1-420B-8A5D-3A1FB39723C3Q28650506-1AB0E26B-7E8A-4CEE-B263-AD359A323A65Q33699097-C5D2C88D-A932-489B-AE95-D67CFCBE110DQ33918377-9DADA926-F24A-47ED-AAA6-6AD638C9E8A4Q33934368-72F495E9-FE8F-46F1-86F7-1C86D2BBDAE8Q34032309-76041C8C-A47A-43BC-B43B-8230B4D48A97Q34058704-E7A7506C-CBB2-4EF0-9E26-D4DD5707CAEBQ34854231-5F03AC62-CF76-431F-83F6-8F37F1FE968EQ34992083-28B10FE7-5626-4C12-AA52-0065FEC0263EQ34998482-3E3F9D9C-6C86-4B08-B887-DA7C8DEF7058Q35373624-23D9BF27-DB76-4233-9F2C-D53F0DCE6F8EQ35760394-3E7CCC28-364D-4BBF-8BA3-8C81BB213138Q35792726-C3253B64-5BF1-4104-96A0-FE1FBAC3F02EQ36027470-23976439-3487-4300-A4C5-FF279ECFA156Q36378519-659CE70A-8C60-461F-8ECC-BAC480C7CC6DQ36399564-3D6ACE31-6438-4D15-B101-7E738D87DC7DQ36622844-21DD2E22-EE62-4CA3-8609-FE16ED36E7E3Q36844501-8BB6A618-476D-4BDC-9067-B013039BF5A0Q37074720-C4DBF776-13E4-4A1B-9FF7-5948E53CE778Q37138984-F47A9726-5650-4BC8-AF2B-618FDFA57E4FQ37203951-53359F9E-0861-41FE-9299-CBAF426B1085Q37204021-4A6EF62D-FD98-4D6C-9AD7-B4A647334F0FQ37596628-AC090152-4D49-4543-9269-066FDEC65B68Q37681393-EC24E078-C57C-4D44-9879-7C9BE64D23ACQ37901720-0A457438-E8E2-4D20-AB99-6026F9B95356Q40046921-FE752E03-0833-4683-A29F-17E25A0C7549Q40218920-556E3D8A-24F1-4BB1-AFA3-9CDC5C9AECB4Q40267523-8B06F276-A394-43DA-A48E-70C7C512C039Q40376109-27B038F8-0194-406F-8D69-DD11998360F7Q40459784-07D57D63-FEA5-4CD0-9490-C813AE8D6598Q40711739-9BA93F6C-6CBA-4EDA-88EA-E6124CCA286EQ41774677-9D6ABA7A-3F2B-49B8-8827-42DE6F823667Q42839214-CC435FEE-FFAD-47ED-ADCB-545DA0FB3139Q43226900-3ECAF202-0E62-49FF-9CCD-A0B8A3B058F9
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Timothy D Warner
@ast
Timothy D Warner
@en
Timothy D Warner
@es
Timothy D Warner
@nl
Timothy D Warner
@sl
type
label
Timothy D Warner
@ast
Timothy D Warner
@en
Timothy D Warner
@es
Timothy D Warner
@nl
Timothy D Warner
@sl
prefLabel
Timothy D Warner
@ast
Timothy D Warner
@en
Timothy D Warner
@es
Timothy D Warner
@nl
Timothy D Warner
@sl
P1053
A-1980-2009
P106
P21
P31
P3829
P496
0000-0003-3988-4408